Pipeline Lundbeck preps for key bexicaserin data around year-end PharmaphorumLundbeck has completed patient randomisation in a pivotal trial of epilepsy candidate bexicaserin, one of its major growth hopes.NeuroscienceRead full story pharminent July 20, 2026 (Last updated: July 20, 2026) Pharmaphorum Lundbeck has completed patient randomisation in a pivotal trial of epilepsy candidate bexicaserin, one of its major growth hopes. Neuroscience Read full story Post navigation Previous: Samsung Biologics to acquire PolyPeptide in $1.81bn cash dealNext: Lilly’s AtaiBeckley buy validates space as Big Pharma takes note of psychedelics Related Stories Pipeline Beyond GLP1s: The race for nextgen obesity drugs starts in the preclinical models pharminent September 2, 2026 Pipeline Bausch + Lomb advances dry eye disease drug to Phase 3 despite mid-stage fail pharminent August 25, 2026 Pipeline Chasing Dupixent, a biotech aims to make better antibody drugs for eczema pharminent August 11, 2026